Abstracts tagged "Sjogren’s syndrome and plasma cells"

Abstract Number: 1773 • 2012 ACR/ARHP Annual Meeting
Hyperammaglobulinemia in Primary Sjögren’s Syndrome Is Induced by Triggering of TLR7 and 9
Susanna Brauner¹, Marika Kvarnstrom¹, Gunnel Nordmark² and Marie Wahren-Herlenius¹, ¹Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Background/Purpose: Multiple B cell aberrances have been linked to primary Sjögren’s syndrome (pSS), including autoantibody production and a skewed B cell differentiation. Further, approximately 50%…
Abstract Number: 516 • 2012 ACR/ARHP Annual Meeting
Characterization of Dominant B- and Plasma Cell Clones in Patients with Primary Sjögren’s Syndrome and Patients with Sicca Syndrome
Marieke E. Doorenspleet¹, Erlin Haecke², Paul L. Klarenbeek¹, Annie Visser³, Rebecca E. Esveldt¹, Fred Spijkervet⁴, Paul-Peter Tak⁵, Hendrika Bootsma⁶, Niek de Vries⁷ and Frans Kroese⁸, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ²Department of Rheumatology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁷Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁸University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune exocrinopathy characterized by chronic inflammation and destruction of the salivary and lacrimal glands. Infiltration of B and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].